Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection

Arthritis and Rheumatism

Volumn 64, Issue 2, 2012, Pages 346-349

  Fiorentino, David ^a,b   Casciola Rosen, Livia ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; TRANSCRIPTION FACTOR; TRANSCRIPTION INTERMEDIARY FACTOR 1 ANTIBODY; TRANSCRIPTION INTERMEDIARY FACTOR 1ALPHA; TRANSCRIPTION INTERMEDIARY FACTOR 1ALPHA ANTIBODY; TRANSCRIPTION INTERMEDIARY FACTOR 1BETA; TRANSCRIPTION INTERMEDIARY FACTOR 1DELTA; TRANSCRIPTION INTERMEDIARY FACTOR 1GAMMA; TRANSCRIPTION INTERMEDIARY FACTOR 1GAMMA ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; AUTOIMMUNITY; CELL FUNCTION; DERMATOMYOSITIS; DISEASE ASSOCIATION; HUMAN; NEOPLASM; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

AUTOANTIBODIES; AUTOANTIGENS; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS;

EID: 84856381232     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33402     Document Type: Review

References (18)

1. Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77: 1019-38. (Pubitemid 20370993)
2. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M,. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases: a marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 1983; 26: 604-11. (Pubitemid 13090012)
3. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193-200.
4. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L,. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25-34.
5. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-9. (Pubitemid 44737181)
6. Selva-O'Callaghan A, Trallero-Araguas E, Grau-Junyent JM, Labrador-Horrillo M,. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 2010; 22: 627-32.
7. Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarasai T, Miller FW,. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis [abstract]. Arthritis Rheum 2006; 54 Suppl: S518.
8. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012; 64: 513-22.
9. Kawai T, Akira S,. Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins. EMBO Mol Med 2011; 3: 513-27.
10. Agricola E, Randall RA, Gaarenstroom T, Dupont S, Hill CS,. Recruitment of TIF1γ to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell 2011; 43: 85-96.
11. Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature 2010; 468: 927-32.
12. Khetchoumian K, Teletin M, Tisserand J, Mark M, Herquel B, Ignat M, et al. Loss of Trim24 (Tif1α) gene function confers oncogenic activity to retinoic acid receptor α. Nat Genet 2007; 39: 1500-6. (Pubitemid 350191338)
13. Chambon M, Orsetti B, Berthe ML, Bascoul-Mollevi C, Rodriguez C, Duong V, et al. Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer. Am J Pathol 2011; 178: 1461-9.
14. Iyengar S, Farnham PJ,. KAP1 protein: an enigmatic master regulator of the genome. J Biol Chem 2011; 286: 26267-76.
15. Kamitani S, Ohbayashi N, Ikeda O, Togi S, Muromoto R, Sekine Y, et al. KAP1 regulates type I interferon/STAT1-mediated IRF-1 gene expression. Biochem Biophys Res Commun 2008; 370: 366-70.
16. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100. (Pubitemid 32094911)
17. Kijanka G, Hector S, Kay EW, Murray F, Cummins R, Murphy D, et al. Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut 2010; 59: 69-78.
18. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591-601. (Pubitemid 40289549)